H. Lundbeck A/S (OTCMKTS:HLUYY – Get Rating)’s share price crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $22.00 and traded as low as $22.00. H. Lundbeck A/S shares last traded at $22.00, with a volume of 7,500 shares traded.
Wall Street Analyst Weigh In
Separately, Citigroup assumed coverage on H. Lundbeck A/S in a research report on Monday, January 23rd. They issued a “neutral” rating for the company. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $36.50.
H. Lundbeck A/S Trading Down 0.0 %
The stock has a 50-day simple moving average of $22.00 and a 200 day simple moving average of $22.00. The company has a current ratio of 1.15, a quick ratio of 0.71 and a debt-to-equity ratio of 0.32. The company has a market cap of $21.91 billion, a price-to-earnings ratio of 25.00 and a beta of 0.68.
About H. Lundbeck A/S
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.
Recommended Stories
- Get a free copy of the StockNews.com research report on H. Lundbeck A/S (HLUYY)
- How to Calculate Stock Growth
- 7 Best Retail Stocks to Invest in
- 3 Home Improvement Stocks to Renovate Your Portfolio
- Beam Global Shines Brightly in the EV Infrastructure Space
- Canoo Bottoms As Production Ramp Gets CloserÂ
Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.